DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Given Average Rating of “Hold” by Brokerages

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) have received an average recommendation of “Hold” from the fourteen brokerages that are covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $13.5455.

Several brokerages have issued reports on XRAY. Citigroup began coverage on DENTSPLY SIRONA in a research note on Wednesday, April 15th. They issued a “sell” rating and a $10.00 price target on the stock. Barclays dropped their price target on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research note on Thursday, June 4th. Robert W. Baird boosted their price target on DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. Mizuho dropped their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Finally, UBS Group dropped their price target on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th.

Insider Buying and Selling at DENTSPLY SIRONA

In other news, Director Brian P. Mckeon bought 10,000 shares of the stock in a transaction dated Friday, June 12th. The shares were bought at an average cost of $10.12 per share, with a total value of $101,200.00. Following the completion of the transaction, the director directly owned 10,000 shares of the company’s stock, valued at $101,200. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Michael J. Barber bought 15,175 shares of the stock in a transaction dated Thursday, June 11th. The shares were purchased at an average cost of $9.88 per share, for a total transaction of $149,929.00. Following the completion of the transaction, the director directly owned 55,943 shares of the company’s stock, valued at $552,716.84. This trade represents a 37.22% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 35,160 shares of company stock valued at $351,179. 0.46% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On DENTSPLY SIRONA

A number of institutional investors have recently modified their holdings of XRAY. Southpoint Capital Advisors LP acquired a new position in shares of DENTSPLY SIRONA during the first quarter worth approximately $116,000,000. AQR Capital Management LLC raised its position in shares of DENTSPLY SIRONA by 109.8% during the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after purchasing an additional 6,970,086 shares during the period. Armistice Capital LLC raised its position in shares of DENTSPLY SIRONA by 1,044.0% during the third quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock worth $72,790,000 after purchasing an additional 5,234,587 shares during the period. Jacobs Levy Equity Management Inc. raised its position in shares of DENTSPLY SIRONA by 662.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock worth $58,480,000 after purchasing an additional 4,003,606 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in shares of DENTSPLY SIRONA by 827.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after purchasing an additional 2,172,343 shares during the period. 95.70% of the stock is owned by institutional investors and hedge funds.

DENTSPLY SIRONA Price Performance

DENTSPLY SIRONA stock opened at $10.20 on Friday. The stock’s 50 day moving average is $10.77 and its 200 day moving average is $11.67. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.53 and a quick ratio of 0.98. The firm has a market cap of $2.04 billion, a P/E ratio of -3.24, a P/E/G ratio of 1.21 and a beta of 0.89. DENTSPLY SIRONA has a one year low of $9.40 and a one year high of $17.09.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The company had revenue of $880.00 million during the quarter, compared to analyst estimates of $841.80 million. DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.DENTSPLY SIRONA’s revenue was up .1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.43 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, research analysts expect that DENTSPLY SIRONA will post 1.42 EPS for the current year.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.